Hematologic Malignancies

Redefining Prognosis for Hematologic Cancers in Older Adults by Age

Redefining Prognosis for Hematologic Cancers in Older Adults by Age

By

A report on how variations in the effects of geriatric syndromes and aging can affect treatment modality choices and outcomes for the eldest older adults with hematologic cancers.

Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments

Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments

By

Study data suggest that cognitive impairments may be associate with worse survival among patients with hematologic cancer.

FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment

FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment

By

The US FDA granted approval to fostamatinib (Tavalisse), a kinase inhibitor, for the treatment of thrombocytopenia in patients with chronic IPT who have had an insufficient response to a previous treatment.

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

By

The ALLIVE trial sought to determine if eLPI levels were predictive of iron-related toxicity and mortality after HCT in patients with AML or MDS.

Patients Identify Critical Elements of Support in Hematologic Cancers

Patients Identify Critical Elements of Support in Hematologic Cancers

By

A cross-sectional study asked patients with hematologic cancers to name the components of care they felt were most crucial to their perception of optimal care.

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms

By

Researchers investigated the antileukemic activity of metformin and ruxolitinib alone and in combination in patients with myeloproliferative neoplasms.

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

By

A retrospective study evaluated timing, frequency, dosing, and other factors related to bisphosphonate therapy in patients with multiple myeloma.

Self-efficacy Measure May Be Used to Drive Interventions Post-SCT in Hematologic Cancers

Self-efficacy Measure May Be Used to Drive Interventions Post-SCT in Hematologic Cancers

By

Researchers present findings of a study assessing the value of SESM evaluations in patients with hematologic cancer prior to undergoing SCT at the NACNS 2018 Annual Conference.

Cardiovascular Disease Risks Greater With ITP, Especially After Splenectomy

Cardiovascular Disease Risks Greater With ITP, Especially After Splenectomy

By

Idiopathic thrombocytopenic purpura (ITP) may be linked to an increased risk of cardiovascular disease, but studies have not been conclusive.

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

By

Researchers report on their findings of a retrospective study that compared pomalidomide plus dexamethasone vs dexamethasone alone in patients with relapsed/refractory multiple myeloma.

ITP Treatment Outcomes Not Improved With Intravenous vs Oral Corticosteroids

ITP Treatment Outcomes Not Improved With Intravenous vs Oral Corticosteroids

By

In this prospective study, researchers sought to compare the effectiveness of IV methylprednisolone vs oral prednisone in hospitalized patients with newly diagnosed ITP.

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

By

A retrospective chart study demonstrated the effectiveness of fosfomycin as an antibacterial prophylaxis for febrile neutropenia in patients with hematologic cancer.

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

By

In this randomized trial, investigators sought to determine the effectiveness of high-dose dexamethasone vs conventional prednisone therapy in treatment-naïve patients with ITP. Results were presented at ASH 2017.

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

By

A retrospective study, presented at ASH 2017, determined the effectiveness of aspirin in reducing risk of VTE in patients with multiple myeloma at high risk of developing VTE.

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera

By

Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.

Ibrutinib Effective As First-line Therapy in Waldenström's Macroglobulinemia

Ibrutinib Effective As First-line Therapy in Waldenström's Macroglobulinemia

By

Ibrutinib — a Bruton tyrosine kinase inhibitor — is currently used among patients with WM who have previously received treatment. This prospective, phase 2 study sought to determine its efficacy as a first-line therapy in treatment-naive patients.

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

By

A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.

4R+3Dex Regimen May Lead to Durable Complete Response in Pediatric Chronic ITP

4R+3Dex Regimen May Lead to Durable Complete Response in Pediatric Chronic ITP

By

Young patients with chronic ITP may experience relapse within 5 years of completing therapy. In this study, investigators sought to determine if the 4R+3Dex regimen for chronic ITP would improve response rates in pediatric patients with the disease.

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

By

In this analysis, researchers measured the impact and effectiveness of supportive treatments for moderate to severe anemia in patients with lymphoma or multiple myeloma, based on patient-reported outcomes.

Vemurafenib Granted FDA Approval as First Drug to Treat Erdheim-Chester Disease

Vemurafenib Granted FDA Approval as First Drug to Treat Erdheim-Chester Disease

By

Indications for vemurafenib are expanded to include BRAF V600 mutation-positive Erdheim-Chester disease, an extremely rare non-Langerhans cell histiocytosis. FDA approval is based on results from the phase 2 VE-BASKET study.

FDA Discontinues ESA APPRISE Risk Evaluation and Mitigation Strategy Program

FDA Discontinues ESA APPRISE Risk Evaluation and Mitigation Strategy Program

By

Why was the ESA APPRISE risk evaluation and mitigation strategy program discontinued?

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib is a treatment option for patients with mantle cell lymphoma who have not responded to prior treatment.

Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP

Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP

By

Previous studies determined the effectiveness of 6 months of therapy with eltrombopag in patients with ITP. In this analysis, researchers extended 4 clinical trials to assess efficacy and safety of eltrombopag therapy for more than 6 months in patients with ITP.

Defibrotide an Effective Option for SOS/VOD in Patients Undergoing HSCT

Defibrotide an Effective Option for SOS/VOD in Patients Undergoing HSCT

By

Sinusoidal obstruction syndrome (or hepatic veno-occlusive disease), a complication observed in patients who undergo HSCT, is managed with defibrotide. In this study, investigators assessed its efficacy and patient response to therapy.

Complications and Management of Coagulation Disorders in Leukemia Patients

Complications and Management of Coagulation Disorders in Leukemia Patients

[Blood and Lymphatic Cancer: Targets and Therapy] Investigators conduct 4 case studies that illustrate a range of coagulation disorders that can develop in patients with leukemia to elucidate the rationale and process of specific treatment options.

A Case of Newly Diagnosed PCV After Relapse TTP Complicated by Undiagnosed RA

A Case of Newly Diagnosed PCV After Relapse TTP Complicated by Undiagnosed RA

By

This case of a 63-year-old African American male with a complicated history illustrates the need for a comprehensive risk assessment of thrombosis in patients with primary polycythemia vera, especially those with concomitant conditions that predispose to thrombosis.

Dapsone, Danazol, Hydroxychloroquine Are Potential Second-line Options in ITP

Dapsone, Danazol, Hydroxychloroquine Are Potential Second-line Options in ITP

By

A retrospective analysis of 28 studies determined that overall response rates for patients with ITP were similar treated with hydroxychloroquine, danazol, or dapsone in the second-line setting were similar.

Rituximab vs Splenectomy: Response Similar in Immune Thrombocytopenic Purpura

Rituximab vs Splenectomy: Response Similar in Immune Thrombocytopenic Purpura

By

Results of a retrospective single-center study showed that response to rituximab vs splenectomy as second-line therapy for steroid-refractory ITP was not significantly different between the 2 treatments.

Combination of Western Care With Chinese Medicine Shows Potential in ITP

Combination of Western Care With Chinese Medicine Shows Potential in ITP

By

The pathogenesis of idiopathic thrombocytopenic purpura (ITP) may be associated with Th17 helper T cells.

Role of Polymorphisms in Idiopathic Thrombocytopenic Purpura: A Review

Role of Polymorphisms in Idiopathic Thrombocytopenic Purpura: A Review

By

The main cause of ITP remains unidentified; however, researchers suggest that certain polymorphisms in respective genes are potential factors for ITP.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs